CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies

This publication has 30 references indexed in Scilit:

• Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome
  Blood, 2004
• Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors
  Bone Marrow Transplantation, 2003
• Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation
  Bone Marrow Transplantation, 2003
• Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation
  Leukemia, 2003
• HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?
  Bone Marrow Transplantation, 2003
• Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings
  Blood, 2002
• Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial
  Transplantation and Cellular Therapy, 2000
• Allogeneic peripheral blood stem cell transplantation for haematological malignancies – an analysis of kinetics of engraftment and GVHD risk
  Bone Marrow Transplantation, 1997
• Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings
  New England Journal of Medicine, 1985
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958